Fundraising FoxRinascera Therapeutics
Boston, US · Founded 2025 · 2 known investors
Find your way into Rinascera Therapeutics
Sign up to see every warm intro you have to Rinascera Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Rinascera Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Rinascera Therapeutics develops treatments for rare genetic skin diseases, with drug candidates targeting conditions such as Gorlin Syndrome and Dystrophic Epidermolysis Bullosa. It operates in the biotechnology and therapeutics sector focused on dermatological genetic disorders.
Founders & leadership
NE
Nichola EliovitsExecutive
MD
Max DawsonExecutiveMax Dawson is Chief Operating Officer and Co-Founder of Rinascera Therapeutics, a clinical-stage biotechnology company developing therapies for rare dermatologic diseases. He brings more than 25 years of biotechnology experience, including prior roles as Chief Operating Officer at DermBiont and positions in finance, business development, and operations at companies including Vertex Pharmaceuticals, Merck Serono, Dyax, and Adagene; he holds an MBA from Babson College and an undergraduate degree from Bates College.
KB
Karl BeutnerExecutive
Board
DY
Investors · 2
Reported raises · per SEC filings
Form D private placements$2.5M disclosed across 1 round · 2025
▶$2.5MraisedOct 2025 · 3 investors · BiotechnologyRule 506(b)
▶$2.5MraisedOct 2025 · 3 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Nichola EliovitsExecutive Officer, Director
- Max DawsonExecutive Officer
- Daniel YadegarDirector
- Karl BeutnerExecutive Officer, Director
- Offering amount
- $2.5M
- Amount sold
- $2.5M
- First sale
- Sep 2025
- Incorporated
- Corporation, Delaware, 2025
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Rinascera Therapeutics do?
- Rinascera Therapeutics develops treatments for rare genetic skin diseases, with drug candidates targeting conditions such as Gorlin Syndrome and Dystrophic Epidermolysis Bullosa. It operates in the biotechnology and therapeutics sector focused on dermatological genetic disorders.
- Who are Rinascera Therapeutics's investors?
- Rinascera Therapeutics's investors include Olive Tree Capital, Newpath Partners.
- How much funding has Rinascera Therapeutics raised?
- Rinascera Therapeutics has disclosed $2.5M raised across 1 round.
- Where is Rinascera Therapeutics headquartered?
- Rinascera Therapeutics is headquartered in Boston, US.